AR011106A1 - COMPOSICIoN FARMACÉUTICA PARA EL TRAMIENTO O PREVENCI.ON DE LA DIABETES MELLITUS TIPO 2, - Google Patents

COMPOSICIoN FARMACÉUTICA PARA EL TRAMIENTO O PREVENCI.ON DE LA DIABETES MELLITUS TIPO 2,

Info

Publication number
AR011106A1
AR011106A1 ARP980100471A ARP980100471A AR011106A1 AR 011106 A1 AR011106 A1 AR 011106A1 AR P980100471 A ARP980100471 A AR P980100471A AR P980100471 A ARP980100471 A AR P980100471A AR 011106 A1 AR011106 A1 AR 011106A1
Authority
AR
Argentina
Prior art keywords
prevention
treatment
diabetes mellitus
pharmaceutical composition
mellitus type
Prior art date
Application number
ARP980100471A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21894047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR011106(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR011106A1 publication Critical patent/AR011106A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un medicamento oral para el tratamiento o la prevencion de la diabetes melitus tipo II, que contiene una cantidad efectiva de un inhibidorgastrointestinal de lipasa, que es la tetrahidrolipstatina, el uso de un inhibidor gastrointestinalde lipasa para la fabricacion de un medicamentooral.
ARP980100471A 1997-02-05 1998-02-03 COMPOSICIoN FARMACÉUTICA PARA EL TRAMIENTO O PREVENCI.ON DE LA DIABETES MELLITUS TIPO 2, AR011106A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3738397P 1997-02-05 1997-02-05

Publications (1)

Publication Number Publication Date
AR011106A1 true AR011106A1 (es) 2000-08-02

Family

ID=21894047

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100471A AR011106A1 (es) 1997-02-05 1998-02-03 COMPOSICIoN FARMACÉUTICA PARA EL TRAMIENTO O PREVENCI.ON DE LA DIABETES MELLITUS TIPO 2,

Country Status (28)

Country Link
US (1) US6147108A (es)
EP (1) EP1017408B1 (es)
JP (1) JP2001509173A (es)
KR (1) KR100479968B1 (es)
CN (1) CN1154505C (es)
AR (1) AR011106A1 (es)
AT (1) ATE292975T1 (es)
AU (1) AU740375B2 (es)
BR (1) BR9807655A (es)
CA (1) CA2278854C (es)
CZ (1) CZ295567B6 (es)
DE (1) DE69829763T2 (es)
DK (1) DK1017408T3 (es)
ES (1) ES2239799T3 (es)
HK (1) HK1025251A1 (es)
HU (1) HU230834B1 (es)
ID (1) ID22650A (es)
IL (1) IL131007A0 (es)
ME (1) ME00578A (es)
NO (1) NO324452B1 (es)
NZ (1) NZ336755A (es)
PL (1) PL191222B1 (es)
PT (1) PT1017408E (es)
RU (1) RU2201272C2 (es)
TR (1) TR199901853T2 (es)
WO (1) WO1998034630A1 (es)
YU (1) YU34199A (es)
ZA (1) ZA98753B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239799T3 (es) * 1997-02-05 2005-10-01 F. Hoffmann-La Roche Ag Uso de tetrahidrolipstatina en el tratamiento de la diabetes tipo ii.
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
ES2324280T3 (es) 2000-03-14 2009-08-04 Unilever N.V. Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos.
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US9174176B2 (en) * 2003-01-09 2015-11-03 Disperse Systems, Inc. Ultrasonic dispersion apparatus, system, and method
US7510849B2 (en) * 2004-01-29 2009-03-31 Glucolight Corporation OCT based method for diagnosis and therapy
NZ553263A (en) 2004-07-19 2010-06-25 Biocon Ltd Insulin-oligomer conjugates, formulations and uses thereof
US7254429B2 (en) 2004-08-11 2007-08-07 Glucolight Corporation Method and apparatus for monitoring glucose levels in a biological tissue
US8036727B2 (en) 2004-08-11 2011-10-11 Glt Acquisition Corp. Methods for noninvasively measuring analyte levels in a subject
AU2006235535A1 (en) 2005-04-13 2006-10-19 Glt Acquisition Corp. Method for data reduction and calibration of an OCT-based blood glucose monitor
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
DE602007008567D1 (de) * 2007-09-12 2010-09-30 Mader S R L Pharmazeutische Zusammensetzungen zur oralen Verabreichung bei der Behandlung von Adipositas-Patienten
EP2219614A1 (en) * 2007-10-15 2010-08-25 Inventis DDS Pvt Limited Pharmaceutical composition of orlistat
WO2009050738A2 (en) 2007-10-16 2009-04-23 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
US8768423B2 (en) 2008-03-04 2014-07-01 Glt Acquisition Corp. Multispot monitoring for use in optical coherence tomography
US8309107B2 (en) * 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
FR3017536B1 (fr) * 2014-02-18 2017-05-26 Univ La Rochelle Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
EP3429567B1 (en) * 2016-03-16 2024-01-10 The J. David Gladstone Institutes Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents
US20190022061A1 (en) * 2017-07-21 2019-01-24 Kieu Hoang Statins (Atorvastatin) can lower blood sugar level in diabetic

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) * 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA2035972C (en) * 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
US5345056A (en) * 1991-12-12 1994-09-06 Motorola, Inc. Plasma based soldering by indirect heating
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
JP3532999B2 (ja) * 1995-03-24 2004-05-31 株式会社ロッテ 新規なタンニン類およびこれを有効成分とするリパーゼ阻害剤
JPH09227398A (ja) * 1996-02-20 1997-09-02 Zeria Pharmaceut Co Ltd 抗肥満剤
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
ES2239799T3 (es) * 1997-02-05 2005-10-01 F. Hoffmann-La Roche Ag Uso de tetrahidrolipstatina en el tratamiento de la diabetes tipo ii.

Also Published As

Publication number Publication date
EP1017408B1 (en) 2005-04-13
DK1017408T3 (da) 2005-08-01
ME00578A (en) 2011-12-20
NO324452B1 (no) 2007-10-22
DE69829763T2 (de) 2006-04-13
HUP0001014A3 (en) 2000-12-28
AU740375B2 (en) 2001-11-01
JP2001509173A (ja) 2001-07-10
HK1025251A1 (en) 2000-11-10
WO1998034630A1 (en) 1998-08-13
CN1154505C (zh) 2004-06-23
RU2201272C2 (ru) 2003-03-27
ZA98753B (en) 1998-08-05
KR20000070733A (ko) 2000-11-25
TR199901853T2 (xx) 1999-12-21
NO993717D0 (no) 1999-07-30
EP1017408A1 (en) 2000-07-12
ATE292975T1 (de) 2005-04-15
ES2239799T3 (es) 2005-10-01
HUP0001014A2 (hu) 2000-08-28
AU6616998A (en) 1998-08-26
PL334975A1 (en) 2000-03-27
HU230834B1 (hu) 2018-07-30
CA2278854A1 (en) 1998-08-13
NO993717L (no) 1999-10-04
CZ265199A3 (cs) 2000-02-16
BR9807655A (pt) 2000-02-15
CA2278854C (en) 2014-03-04
ID22650A (id) 1999-12-02
DE69829763D1 (de) 2005-05-19
PL191222B1 (pl) 2006-03-31
PT1017408E (pt) 2005-07-29
NZ336755A (en) 2001-06-29
YU34199A (sh) 2002-08-12
IL131007A0 (en) 2001-01-28
US6147108A (en) 2000-11-14
KR100479968B1 (ko) 2005-03-30
CZ295567B6 (cs) 2005-08-17
CN1246798A (zh) 2000-03-08

Similar Documents

Publication Publication Date Title
AR011106A1 (es) COMPOSICIoN FARMACÉUTICA PARA EL TRAMIENTO O PREVENCI.ON DE LA DIABETES MELLITUS TIPO 2,
ES2187756T3 (es) Uso de una composicion farmaceutica que comprende un peptido supresor del apetito.
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
BR0115055A (pt) Terapia de combinação compreendendo agentes anticonvulsantes e antidiabéticos
BR0112519A (pt) Derivados anticonvulsivantes úteis para prevenir o desenvolvimento de diabetes melito do tipo ii e sìndrome x
BR9709395A (pt) Calçado aperfeiçoado
BR9814592B1 (pt) composto azapolicìclico condensado com arila, composição farmacêutica contendo o mesmo e seu uso na fabricação de um medicamento.
DE69611369D1 (de) Sublingual oder bukkal verabreichte arzneistoffe mit gesteuerter freisetzung
NO971206D0 (no) Forlenget-frigjöringsformulering
KR950005319A (ko) 약학적 조성물
AR033796A1 (es) Composicion farmaceutica
AR034231A1 (es) Composicion farmaceutica que contiene mosaprida y pancreatina
CY1107939T1 (el) Συνεργικοι φαρμακευτικοι συνδυασμοι για την προληψη ή την αγωγη του διαβητη
ES2196855T3 (es) Uso de un material de polimero modular de la viscosidad para reducir la erosion de los dientes.
NO952207D0 (no) Anvendelse av 2-amino-6-A-propylamino-4,5,6,7-tetrahydrobenzotiazol (pramipexol) som et antidepresivt legemiddel
RU99118887A (ru) Применение ингибиторов желудочно-кишечной липазы
ES2171590T3 (es) Composicion farmaceutica para el tratamiento de rinitis agudas, que contiene un simpatomimetico y pantotenol y/o acido pantotenico.
NO983530D0 (no) Dihydrobenzofuran og relaterte forbindelser anvendelig som anti-inflammatoriske midler
AR037326A1 (es) Composicion farmaceutica de liberacion prolongada que contiene metformina
BR9813996A (pt) 2-arilbenzo[b]tiofenos úteis para o tratamento de sìndrome da privação de estrogênio
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
ES2156616T3 (es) (r)-5-bromo-n-(1-etil-4-metilhexahidro-1h-1,4-diazepan-6-il)-2-metoxi-6-metilamino-3-piridincarboxamida, procedimiento para su produccion y composicion medicinal que la contiene.
DK88087A (da) Tricyklisk 5-(3-chlor-6-methyl-5,5-dioxo-6,11-dihydro-dibenzo-(c,f)-(1,2)-thiazepin-11-yl)-amino-pentansyrederivat, fremgangsmaade til fremstilling deraf og farmaceutiske midler indeholdende dem
PT896821E (pt) Uma nova composicao farmaceutica para inalacao que contem cr 2039 (andolast)
GT199900087A (es) Terapia de combinacion para la fragilidad musculoesqueletica.

Legal Events

Date Code Title Description
FC Refusal